Efficacy and Safety of PD-1 Inhibitors and Targeted Drugs Combined with Radiotherapy in First-Line Treatment of Oligometastatic Hepatocellular Carcinoma

被引：0
|
作者：
Zhu, K. [1 ]
Liu, J. [2 ]
Dou, X. [1 ]
Zhang, X. [1 ]
Xu, L. [1 ]
Shi, P. [2 ]
Shi, F. [1 ]
Yue, J. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Shandong First Med Univ, Shandong Canc Hosp, Jinan, Shandong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3126
引用
收藏
页码：E509 / E509
页数：1
相关论文
共 50 条
  • [1] The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma
    Liu, Qing-Qing
    Wang, Xiang-Xu
    Ji, Hongchen
    Dou, Qiong-Yi
    Zhang, Hong-Mei
    MEDICAL ONCOLOGY, 2024, 41 (05)
  • [2] Efficacy and safety of regorafenib and PD-1 combined with cryoablation in the treatment of advanced hepatocellular carcinoma after second-line targeted therapy
    Chen, Yan
    Kong, Huifang
    Wang, Sihao
    Zhang, Wei
    Chang, Xiujuan
    Huang, Jiagan
    Dong, Zheng
    Gao, Xudong
    Yang, Bin
    Zhang, Huixin
    Zhang, Bailong
    Yang, Yongping
    Zeng, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer
    Liu, Haonan
    Pan, Di
    Yao, Zhiyuan
    Wang, Hongmei
    Li, Yuqi
    Qin, Xiaobing
    Qu, Pengfei
    Tang, Juanjuan
    Han, Zhengxiang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 139
  • [4] Efficacy and safety analysis of PD-1 combined with regorafenib in the treatment of advanced hepatocellular carcinoma
    Dong, Lu
    Wang, Pengbin
    Pan, Yan
    Sun, Naiying
    Yin, Gang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (06): : 2554 - 2562
  • [5] Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study
    Xu, Jing
    Wang, Xin
    Jia, Zhenya
    Sun, Guoping
    MEDICINE, 2025, 104 (11)
  • [6] Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer
    Duan, Yanan
    Qin, Wenru
    Yang, Linlin
    Zou, Bing
    Qie, Wenting
    Song, Ruiting
    Xue, Lu
    Wang, Linlin
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 55 - 65
  • [7] Analysis of the effectiveness and safety of lenvatinib/bevacizumab combined with PD-1/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma
    Zhao, Lu
    Zhang, Zhengfeng
    Wang, Dazhen
    Yang, Liu
    Liu, Ze
    Lou, Changjie
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
  • [8] Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors in the treatment of hepatocellular carcinoma: A meta-analysis and systematic review
    Zhang, Baoyan
    Su, Linfeng
    Lin, Yonghua
    ONCOLOGY LETTERS, 2024, 28 (01)
  • [9] Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy
    Wang, Haochen
    Xiao, Weizhong
    Han, Yanjing
    Cao, Shasha
    Zhang, Zhiyuan
    Chen, Guang
    Hu, Yuefeng
    Jin, Long
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1248 - 1254
  • [10] Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma
    Wang, Quan
    Ji, Xiaoquan
    Sun, Jing
    Zhang, Aimin
    Jia, Jun
    Zhang, Teng
    Li, Wengang
    Duan, Xuezhang
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1363 - 1376
12345